

c) Remarks

The claims are 15-24 with claims 15 and 20 being independent. Former claims 1, 2, 5-19 and 12-14 have been cancelled. The claims have been amended to better define the intended invention.

Independent claim 15 is supported by Ex. Comp. Nos. 519 and 526 in Table 17 on page 34. New claim 20 is supported by Ex. Comp. Nos. 7, 14, 21, 28, 35, 42, 49 (Table 1); 56, 63, 70, 77, 84, 91, 98 (Table 2); 105, 112, 119, 126, 133, 140, 147, 154 (Table 3); 161, 168, 175, 182, 189, 196, 203 (Table 4); 210, 217, 224, 231, 238, 245, 252, 259 (Table 5); 266, 273, 280, 287, 294, 301 and 308 (Table 6).

Claims 16-19 and 21-24 generally correspond to former claims 8 and 12-14.

The rejection of claims 1, 2, 5, 8, 9 and 12-14 under 35 U.S.C. § 112, second paragraph, as being indefinite has been rendered moot by their cancellation.

The Examiner had rejected the claims as anticipated by Burn et al. (WO '552). The claims were also rejected as obvious over Igarashi '782. Finally, the claims were provisionally rejected as an obviousness-type double patenting over claims 1-4 and 11-16 of Application No. 10/073,011 and over claims 1, 8-15, 21, 39, 41 and 44-47 of co-pending Application No. 10/073,012. The grounds of rejection are respectfully traversed.

New independent claim 15 and the claims dependent on it are characterized by an iridium ligand complex in which a naphthyl group is a substituent to the ligand. In Igarashi, compound (1-45) has a phenyl group, but not naphthyl group connected to the ligand. In addition, the ligand (1-45) does not have a fused phenyl ring.

In addition, in Igarashi compound (1-67) a phenyl ring is fused to the central ligand while in formula (b) of new claim 15, a naphthyl group is attached as a substituent

to the ligand. With regard to new claim 20, none of the compounds in Igarashi have a pyrene group attached as a substituent to the ligand. Burn fails to teach the subject matter of independent claims 15 and 20, especially with regard to the substituents attached to and/or fused to the ligand.


Burn et al. (WO '552) and Igarashi US '782 accordingly, fail to teach or suggest the present claimed compounds or device.

In addition, the subject matter of claims 15 and 20 is not found in the claims of co-pending Application Nos. 10/073,011 or 10/073,012.

It is respectfully requested that this Amendment After Final Rejection be entered since it reduces the issues, that the final rejection be withdrawn, that the claims allowed and that the case passed to issue.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our below listed address.

Respectfully submitted,

  
Attorney for Applicants  
Jason M. Okun  
Registration No. 48,512

FITZPATRICK, CELLA, HARPER & SCINTO  
30 Rockefeller Plaza  
New York, New York 10112-3801  
Facsimile: (212) 218-2200